IMMUNE NETWORK

  • 제25권2호
  • /
  • Pages.5.1-5.19
  • /
  • 2025
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지
DOI QR코드

DOI QR Code

Anti-arthritis Effect of Anti-chitinase-3-like 1 Antibody Through Inhibition of MMP3

  • Dae Hwan Kim (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Ji Eun Yu (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Dong Hun Lee (Department of Biological Sciences, Chonnam National University) ;
  • Min Ji Kim (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Seong Hee Jeon (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Jaesuk Yun (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Dong Ju Son (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Bongcheol Kim (Senelix Co.) ;
  • Yoon Ji Yong (Prestige Biologics Co.) ;
  • Young-soo Lim (Prestige Biologics Co.) ;
  • Tae Hun Kim (Autotelic Bio Co.) ;
  • Azizi Mohammad Khalid (Medical Team & Innovation Center, Bestian Hospital) ;
  • Sang-Bae Han (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Yong Sun Lee (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Jin Tae Hong (College of Pharmacy and Medical Research Center, Chungbuk National University)
  • 투고 : 2024.09.22
  • 심사 : 2025.01.05
  • 발행 : 2025.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Chitinase-3-like 1 (CHI3L1) is a key factor in regulating inflammatory processes and development of rheumatoid arthritis (RA) since is highly produced by synoviocytes and macrophages in the development RA. Collagen-induced arthritis (CIA) model is the most widely used because its pathogenesis is similar to human RA. Thus, we aimed to investigate if anti-CHI3L1 antibody could reduce RA development in the CIA model. To induce CIA, DBA1/J mice were immunized with a type II bovine collagen emulsion in complete Freund's adjuvant, and boosted type II bovine collagen. THP-1 and MH7A cells were used for pro-inflammation responses. Anti-CHI3L1 Ab treatment reduced the RA clinical score and paw thickness of mice. Inflammation-induced matrix metalloproteinase 3 (MMP3) expression was reduced by inhibiting CHI3L1, and MMP3 knockdown suppressed the expression of RA-related inflammatory cytokines in LPS-treated THP-1 and MH7A cells. Our findings suggest that anti-CHI3L1 Ab showed significant anti-arthritic effects by inhibiting MMP3 expression.

키워드

과제정보

This research was supported by "Regional Innovation Strategy (RIS)" through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (MOE) (2021RIS-001).

참고문헌

  1. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, et al. Rheumatoid arthritis. Nat Rev Dis Primers 2018;4:18001. https://doi.org/10.1038/nrdp.2018.1
  2. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 2018;6:15. https://doi.org/10.1038/s41413-018-0016-9
  3. Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, He CH, Takyar S, Elias JA. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 2011;73:479-501. https://doi.org/10.1146/annurev-physiol-012110-142250
  4. Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 like-protein-1 function and its role in diseases. Signal Transduct Target Ther 2020;5:201. https://doi.org/10.1038/s41392-020-00303-7
  5. Coffman FD. Chitinase 3-Like-1 (CHI3L1): a putative disease marker at the interface of proteomics and glycomics. Crit Rev Clin Lab Sci 2008;45:531-562. https://doi.org/10.1080/10408360802334743
  6. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 2010;7:34. https://doi.org/10.1186/1742-2094-7-34
  7. Lee YH, Song GG. Ykl-40 levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis. J Rheum Dis 2019;26:257-263. https://doi.org/10.4078/jrd.2019.26.4.257
  8. Ham HJ, Lee YS, Lee HP, Ham YW, Yun J, Han SB, Hong JT. G721-0282 exerts anxiolytic-like effects on chronic unpredictable mild stress in mice through inhibition of chitinase-3-like 1-mediated neuroinflammation. Front Cell Neurosci 2022;16:793835. https://doi.org/10.3389/fncel.2022.793835
  9. Jeon SH, Lee YS, Yeo IJ, Lee HP, Yoon J, Son DJ, Han SB, Hong JT. Inhibition of chitinase-3-like-1 by k284-6111 reduces atopic skin inflammation via repressing lactoferrin. Immune Netw 2021;21:e22. https://doi.org/10.4110/in.2021.21.e22
  10. Lee YS, Yu JE, Kim MJ, Ham HJ, Jeon SH, Yun J, Song SG, Lee CK, Han SB, Son DJ, et al. New therapeutic strategy for atopic dermatitis by targeting CHI3L1/ITGA5 axis. Clin Transl Med 2022;12:e739. https://doi.org/10.1002/ctm2.739
  11. Kim M, Chang JY, Lee DW, Kim YR, Son DJ, Yun J, Jung YS, Lee DH, Han S, Hong JT. Chitinase 3 like 1 deficiency ameliorates lipopolysaccharide-induced acute liver injury by inhibition of M2 macrophage polarization. Mol Immunol 2023;156:98-110. https://doi.org/10.1016/j.molimm.2023.02.012
  12. Araki Y, Mimura T. Matrix metalloproteinase gene activation resulting from disordred epigenetic mechanisms in rheumatoid arthritis. Int J Mol Sci 2017;18:905. https://doi.org/10.3390/ijms18050905
  13. Wan J, Zhang G, Li X, Qiu X, Ouyang J, Dai J, Min S. Matrix metalloproteinase 3: a promoting and destabilizing factor in the pathogenesis of disease and cell differentiation. Front Physiol 2021;12:663978.  https://doi.org/10.3389/fphys.2021.663978
  14. Chao PZ, Hsieh MS, Cheng CW, Lin YF, Chen CH. Regulation of MMP-3 expression and secretion by the chemokine eotaxin-1 in human chondrocytes. J Biomed Sci 2011;18:86. https://doi.org/10.1186/1423-0127-18-86
  15. Zeisel MB, Druet VA, Wachsmann D, Sibilia J. MMP-3 expression and release by rheumatoid arthritis fibroblast-like synoviocytes induced with a bacterial ligand of integrin α5β1. Arthritis Res Ther 2004;7:R118-R126. https://doi.org/10.1186/ar1462
  16. Chase AJ, Bond M, Crook MF, Newby AC. Role of nuclear factor-κ B activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol 2002;22:765-771. https://doi.org/10.1161/01.ATV.0000015078.09208.92
  17. Leong DJ, Gu XI, Li Y, Lee JY, Laudier DM, Majeska RJ, Schaffler MB, Cardoso L, Sun HB. Matrix metalloproteinase-3 in articular cartilage is upregulated by joint immobilization and suppressed by passive joint motion. Matrix Biol 2010;29:420-426. https://doi.org/10.1016/j.matbio.2010.02.004
  18. Blom AB, van Lent PL, Libregts S, Holthuysen AE, van der Kraan PM, van Rooijen N, van den Berg WB. Crucial role of macrophages in matrix metalloproteinase-mediated cartilage destruction during experimental osteoarthritis: involvement of matrix metalloproteinase 3. Arthritis Rheum 2007;56:147-157.  https://doi.org/10.1002/art.22337
  19. Zhou L, Wang G, Liu X, Song J, Chen L, Xu H. Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis. Arthritis Res Ther 2017;19:250. https://doi.org/10.1186/s13075-017-1449-z
  20. Hattori Y, Kida D, Kaneko A. Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis. Clin Rheumatol 2019;38:181-187. https://doi.org/10.1007/s10067-017-3829-9
  21. Libreros S, Garcia-Areas R, Keating P, Carrio R, Iragavarapu-Charyulu VL. Exploring the role of CHI3L1 in "pre-metastatic" lungs of mammary tumor-bearing mice. Front Physiol 2013;4:392. https://doi.org/10.3389/fphys.2013.00392
  22. Väänänen T, Koskinen A, Paukkeri EL, Hämäläinen M, Moilanen T, Moilanen E, Vuolteenaho K. YKL40 as a novel factor associated with inflammation and catabolic mechanisms in osteoarthritic joints. Mediators Inflamm 2014;2014:215140.
  23. Kang K, Kim K, Lee SR, Kim Y, Lee JE, Lee YS, Lim JH, Lim CS, Kim YJ, Baek SI, et al. Selection and characterization of ykl-40-targeting monoclonal antibodies from human synthetic fab phage display libraries. Int J Mol Sci 2020;21:6354. https://doi.org/10.3390/ijms21176354
  24. Yu JE, Yeo IJ, Son DJ, Yun J, Han SB, Hong JT. Anti-Chi3L1 antibody suppresses lung tumor growth and metastasis through inhibition of M2 polarization. Mol Oncol 2022;16:2214-2234. https://doi.org/10.1002/1878-0261.13152
  25. Ban JO, Kim DH, Lee HP, Hwang CJ, Shim JH, Kim DJ, Kim TM, Jeong HS, Nah SS, Chen H, et al. Anti-arthritis effects of (E)-2,4-bis(p-hydroxyphenyl)-2-butenal are mediated by inhibition of the STAT3 pathway. Br J Pharmacol 2014;171:2900-2912. https://doi.org/10.1111/bph.12619
  26. Lee YS, Lee CH, Bae JT, Nam KT, Moon DB, Hwang OK, Choi JS, Kim TH, Jun HO, Jung YS, et al. Inhibition of skin carcinogenesis by suppression of NF-κB dependent ITGAV and TIMP-1 expression in IL-32γ overexpressed condition. J Exp Clin Cancer Res 2018;37:293. https://doi.org/10.1186/s13046-018-0943-8
  27. Kim KC, Yun J, Son DJ, Kim JY, Jung JK, Choi JS, Kim YR, Song JK, Kim SY, Kang SK, et al. Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1. Theranostics 2018;8:4409-4428. https://doi.org/10.7150/thno.26467
  28. Devarapu SK, Grill JF, Xie J, Weidenbusch M, Honarpisheh M, Vielhauer V, Anders HJ, Mulay SR. Tumor necrosis factor superfamily ligand mRNA expression profiles differ between humans and mice during homeostasis and between various murine kidney injuries. J Biomed Sci 2017;24:77. https://doi.org/10.1186/s12929-017-0383-3
  29. Wang X, Zhu W, Long Q, Chen E, Sun H, Li X, Xu H, Li W, Dong P, He L, et al. The prognostic value and immune correlation of IL18 expression and promoter methylation in renal cell carcinoma. Clin Epigenetics 2023;15:14. https://doi.org/10.1186/s13148-023-01426-8
  30. Wang Z, Wang B, Zhang J, Wu Z, Yu L, Sun Z. Chemokine (C-C motif ) ligand 2/chemokine receptor 2 (CCR2) axis blockade to delay chondrocyte hypertrophy as a therapeutic strategy for osteoarthritis. Med Sci Monit 2021;27:e930053. https://doi.org/10.12659/MSM.930053
  31. Martini AC, Berta T, Forner S, Chen G, Bento AF, Ji RR, Rae GA. Lipoxin A4 inhibits microglial activation and reduces neuroinflammation and neuropathic pain after spinal cord hemisection. J Neuroinflammation 2016;13:75. https://doi.org/10.1186/s12974-016-0540-8
  32. Bardina SV, Michlmayr D, Hoffman KW, Obara CJ, Sum J, Charo IF, Lu W, Pletnev AG, Lim JK. Differential roles of chemokines CCL2 and CCL7 in monocytosis and leukocyte migration during West Nile virus infection. J Immunol 2015;195:4306-4318. https://doi.org/10.4049/jimmunol.1500352
  33. Fang G, Wen X, Jiang Z, Du X, Liu R, Zhang C, Huang G, Liao W, Zhang Z. FUNDC1/PFKP-mediated mitophagy induced by KD025 ameliorates cartilage degeneration in osteoarthritis. Mol Ther 2023;31:3594-3612.  https://doi.org/10.1016/j.ymthe.2023.10.016
  34. Höckendorf U, Yabal M, Herold T, Munkhbaatar E, Rott S, Jilg S, Kauschinger J, Magnani G, Reisinger F, Heuser M, et al. Ripk3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells. Cancer Cell 2016;30:75-91. https://doi.org/10.1016/j.ccell.2016.06.002
  35. Geurts J, Joosten LAB, Takahashi N, Arntz OJ, Glück A, Bennink MB, van den Berg WB, van de Loo FAJ. Computational design and application of endogenous promoters for transcriptionally targeted gene therapy for rheumatoid arthritis. Mol Ther 2009;17:1877-1887. https://doi.org/10.1038/mt.2009.182
  36. Sun Y, Caplazi P, Zhang J, Mazloom A, Kummerfeld S, Quinones G, Senger K, Lesch J, Peng I, Sebrell A, et al. PILRα negatively regulates mouse inflammatory arthritis. J Immunol 2014;193:860-870. https://doi.org/10.4049/jimmunol.1400045
  37. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 2010;38:W214-20. https://doi.org/10.1093/nar/gkq537
  38. Cutolo M, Campitiello R, Gotelli E, Soldano S. The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis. Front Immunol 2022;13:867260. https://doi.org/10.3389/fimmu.2022.867260
  39. Sun S, Bay-Jensen AC, Karsdal MA, Siebuhr AS, Zheng Q, Maksymowych WP, Christiansen TG, Henriksen K. The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. BMC Musculoskelet Disord 2014;15:93. https://doi.org/10.1186/1471-2474-15-93
  40. Joosten LAB, Netea MG, Fantuzzi G, Koenders MI, Helsen MMA, Sparrer H, Pham CT, van der Meer JWM, Dinarello CA, van den Berg WB. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1β. Arthritis Rheum 2009;60:3651-3662. https://doi.org/10.1002/art.25006
  41. Cascão R, Polido-Pereira J, Canhão H, Rodrigues AM, Navalho M, Raquel H, Neves-Costa A, Mourão AF, Resende C, da Silva JA, et al. Caspase-1 is active since the early phase of rheumatoid arthritis. Clin Exp Rheumatol 2012;30:144. PUBMED https://doi.org/10.1136/ard.2010.149096.4
  42. Lee YS, Yu JE, Kim KC, Lee DH, Son DJ, Lee HP, Jung JK, Kim ND, Ham YW, Yun J, et al. A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL-13Rα2-mediated JNK-AP-1 signals. Mol Oncol 2022;16:508-526. https://doi.org/10.1002/1878-0261.13138
  43. Johansen JS, Stoltenberg M, Hansen M, Florescu A, Hørslev-Petersen K, Lorenzen I, Price PA. Serum YKL40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999;38:618-626. https://doi.org/10.1093/rheumatology/38.7.618
  44. Volck B, Johansen JS, Stoltenberg M, Garbarsch C, Price PA, Ostergaard M, Ostergaard K, Løvgreen-Nielsen P, Sonne-Holm S, Lorenzen I. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001;9:203-214. https://doi.org/10.1053/joca.2000.0377
  45. Ham HJ, Lee YS, Yun J, Son DJ, Lee HP, Han SB, Hong JT. K284-6111 alleviates memory impairment and neuroinflammation in Tg2576 mice by inhibition of chitinase-3-like 1 regulating ERK-dependent PTX3 pathway. J Neuroinflammation 2020;17:350. https://doi.org/10.1186/s12974-020-02022-w
  46. Amin AR, Attur M, Abramson SB. Nitric oxide synthase and cyclooxygenases: distribution, regulation, and intervention in arthritis. Curr Opin Rheumatol 1999;11:202-209. https://doi.org/10.1097/00002281-199905000-00009
  47. Murphy G, Knäuper V, Atkinson S, Butler G, English W, Hutton M, Stracke J, Clark I. Matrix metalloproteinases in arthritic disease. Arthritis Res 2002;4 Suppl 3:S39-S49. https://doi.org/10.1186/ar572
  48. Liu S, Deng Z, Chen K, Jian S, Zhou F, Yang Y, Fu Z, Xie H, Xiong J, Zhu W. Cartilage tissue engineering: from proinflammatory and anti\xe2\x80\x91inflammatory cytokines to osteoarthritis treatments (review). Mol Med Rep 2022;25:99. https://doi.org/10.3892/mmr.2022.12615
  49. Väänänen T, Vuolteenaho K, Kautiainen H, Nieminen R, Möttönen T, Hannonen P, Korpela M, Kauppi MJ, Laiho K, Kaipiainen-Seppänen O, et al. Glycoprotein YKL-40: a potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. PLoS One 2017;12:e0183294. https://doi.org/10.1371/journal.pone.0183294
  50. Waszczykowski M, Fabiś-Strobin A, Bednarski I, Narbutt J, Fabiś J. Serum and synovial fluid concentrations of interleukin-18 and interleukin-20 in patients with osteoarthritis of the knee and their correlation with other markers of inflammation and turnover of joint cartilage. Arch Med Sci 2020;18:448-458. https://doi.org/10.5114/aoms.2020.96717
  51. Kanai T, Kondo N, Okada M, Sano H, Okumura G, Kijima Y, Ogose A, Kawashima H, Endo N. The JNK pathway represents a novel target in the treatment of rheumatoid arthritis through the suppression of MMP-3. J Orthop Surg 2020;15:87. https://doi.org/10.1186/s13018-020-01595-9
  52. Konishi H, Kanou SE, Yukimatsu R, Inui M, Sato M, Yamamoto N, Nakano M, Koshiba M. Adenosine inhibits TNFα-induced MMP-3 production in MH7A rheumatoid arthritis synoviocytes via A2A receptor signaling. Sci Rep 2022;12:6033. https://doi.org/10.1038/s41598-022-10012-6
  53. Souslova V, Townsend PA, Mann J, van der Loos CM, Motterle A, D'Acquisto F, Mann DA, Ye S. Allele-specific regulation of matrix metalloproteinase-3 gene by transcription factor NFkappaB. PLoS One 2010;5:e9902. https://doi.org/10.1371/journal.pone.0009902
  54. Zhang Y, Weng Q, Chen J, Li M, Han J. Oroxylin A attenuates IL-1β-induced inflammatory reaction via inhibiting the activation of the ERK and PI3K/AKT signaling pathways in osteoarthritis chondrocytes. Exp Ther Med 2021;21:388. https://doi.org/10.3892/etm.2021.9819
  55. Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009;10:241-247. https://doi.org/10.1038/ni.1703
  56. Van Hove I, Lefevere E, De Groef L, Sergeys J, Salinas-Navarro M, Libert C, Vandenbroucke R, Moons L. MMP3 deficiency alleviates endotoxin-induced acute inflammation in the posterior eye segment. Int J Mol Sci 2016;17:1825.
  57. Liang Y, Song P, Chen W, Xie X, Luo R, Su J, Zhu Y, Xu J, Liu R, Zhu P, et al. Inhibition of caspase-1 ameliorates ischemia-associated blood-brain barrier dysfunction and integrity by suppressing pyroptosis activation. Front Cell Neurosci 2021;14:540669. https://doi.org/10.3389/fncel.2020.540669
  58. Tao T, Luo D, Gao C, Liu H, Lei Z, Liu W, Zhou C, Qi D, Deng Z, Sun X, et al. Src homology 2 domain-containing protein tyrosine phosphatase promotes inflammation and accelerates osteoarthritis by activating β-catenin. Front Cell Dev Biol 2021;9:646386. https://doi.org/10.3389/fcell.2021.646386
  59. García-Arnandis I, Guillén MI, Gomar F, Castejón MA, Alcaraz MJ. Control of cell migration and inflammatory mediators production by CORM-2 in osteoarthritic synoviocytes. PLoS One 2011;6:e24591. https://doi.org/10.1371/journal.pone.0024591
  60. Kwak EJ, Hong JY, Kim MN, Kim SY, Kim SH, Park CO, Kim KW, Lee CG, Elias JA, Jee HM, et al. Chitinase 3-like 1 drives allergic skin inflammation via Th2 immunity and M2 macrophage activation. Clin Exp Allergy 2019;49:1464-1474. https://doi.org/10.1111/cea.13478
  61. Kim EG, Kim MN, Hong JY, Lee JW, Kim SY, Kim KW, Lee CG, Elias JA, Song TW, Sohn MH. Chitinase 3-like 1 contributes to food allergy via M2 macrophage polarization. Allergy Asthma Immunol Res 2020;12:1012-1028. https://doi.org/10.4168/aair.2020.12.6.1012
  62. Lin W, Shen P, Huang Y, Han L, Ba X, Huang Y, Yan J, Li T, Xu L, Qin K, et al. Wutou decoction attenuates the synovial inflammation of collagen-induced arthritis rats via regulating macrophage M1/M2 type polarization. J Ethnopharmacol 2023;301:115802. https://doi.org/10.1016/j.jep.2022.115802
  63. Sekine C, Nanki T, Yagita H. Macrophage-derived delta-like protein 1 enhances interleukin-6 and matrix metalloproteinase 3 production by fibroblast-like synoviocytes in mice with collagen-induced arthritis. Arthritis Rheumatol 2014;66:2751-2761. https://doi.org/10.1002/art.38743
  64. Shams S, Martinez JM, Dawson JRD, Flores J, Gabriel M, Garcia G, Guevara A, Murray K, Pacifici N, Vargas MV, et al. The therapeutic landscape of rheumatoid arthritis: current state and future directions. Front Pharmacol 2021;12:680043. https://doi.org/10.3389/fphar.2021.680043
  65. Santos-Moreno P, Sánchez G, Castro C. Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis: Results of a cohort study. Medicine (Baltimore) 2019;98:e14181. https://doi.org/10.1097/MD.0000000000014181
  66. Bobbio-Pallavicini F, Caporali R, Alpini C, Moratti R, Montecucco C. Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-α treated patients. Ann N Y Acad Sci 2007;1109:287-295. https://doi.org/10.1196/annals.1398.034